PEMPHIGOID GESTATIONIS: A RARE AUTOIMMUNE BLISTERING DISORDER DURING PREGNANCY—A COMPREHENSIVE REVIEW OF IMMUNOPATHOGENESIS, PHARMACOTHERAPY STRATEGIES, PRECISION THERAPEUTICS AND EVIDENCE-BASED CLINICAL MANAGEMENT

Abstract

Pemphigoid gestationis (PG) is a rare, pregnancy-associated autoimmune subepidermal blistering disorder characterized by severe pruritus, erythematous urticarial plaques, and tense vesiculobullous lesions that predominantly develop during the second or third trimester of pregnancy. Although its estimated incidence ranges from approximately one case per 50,000–60,000 pregnancies, PG represents a clinically significant dermatological condition because of its potential maternal morbidity, recurrent nature in subsequent pregnancies, and association with adverse fetal outcomes, including preterm delivery, fetal growth restriction, and transient neonatal blistering resulting from transplacental transfer of pathogenic autoantibodies. The disorder shares immunopathological mechanisms with bullous pemphigoid but exhibits unique pregnancy-related immunological triggers involving aberrant placental expression of basement membrane antigens, maternal loss of immune tolerance, and complement-mediated inflammatory responses. Early recognition remains challenging because the initial manifestations frequently mimic other pregnancy-specific dermatoses, including polymorphic eruption of pregnancy, atopic eruption of pregnancy, intrahepatic cholestasis of pregnancy, and pustular psoriasis of pregnancy, emphasizing the importance of accurate differential diagnosis and multidisciplinary clinical management. This comprehensive review critically evaluates current knowledge regarding the epidemiology, molecular immunopathogenesis, clinical manifestations, diagnostic methodologies, pharmacotherapeutic interventions, precision therapeutic approaches, and evidence-based clinical management of pemphigoid gestationis. Particular emphasis is placed on the immunological mechanisms responsible for disease initiation and progression, including maternal IgG1 autoantibody production against hemidesmosomal proteins, especially collagen XVII (BP180), activation of the classical complement cascade, recruitment of eosinophils, cytokine dysregulation, and subsequent dermoepidermal separation leading to blister formation. Recent advances in immunology have further demonstrated the roles of human leukocyte antigen susceptibility, placental immune dysregulation, T-helper cell imbalance, regulatory T-cell dysfunction, B-cell activation, and inflammatory chemokine signaling pathways that collectively contribute to disease expression and recurrence. Diagnostic evaluation requires integration of characteristic clinical findings with laboratory and histopathological investigations. Histopathological examination typically demonstrates subepidermal blister formation accompanied by eosinophilic infiltration, whereas direct immunofluorescence remains the diagnostic gold standard by demonstrating continuous linear complement C3 deposition, frequently accompanied by IgG, along the basement membrane zone. Additional diagnostic modalities, including indirect immunofluorescence, enzyme-linked immunosorbent assays for BP180 NC16A autoantibodies, and emerging molecular biomarkers, improve diagnostic accuracy, facilitate disease monitoring, and may contribute to individualized therapeutic decision-making. Contemporary differential diagnostic strategies are discussed to distinguish PG from other inflammatory and autoimmune dermatoses encountered during pregnancy. Current pharmacotherapeutic management aims to achieve rapid symptom control while minimizing fetal and maternal risks. First-line therapy generally consists of topical corticosteroids combined with pregnancy-compatible oral antihistamines for mild disease, whereas systemic corticosteroids, particularly prednisone or prednisolone, remain the cornerstone of treatment for moderate-to-severe disease because of their limited placental transfer and favorable safety profile when administered appropriately. Adjunctive therapies, including topical calcineurin inhibitors, corticosteroid-sparing immunosuppressive agents, intravenous immunoglobulin, plasmapheresis, immunoadsorption, and biologic therapies such as rituximab, omalizumab, and dupilumab, are critically evaluated for refractory or severe disease based on emerging clinical evidence. The review further discusses therapeutic monitoring, individualized dose optimization, postpartum management, breastfeeding considerations, recurrence prevention, and adverse-effect surveillance. Advances in precision medicine have created opportunities for personalized management of pemphigoid gestationis through biomarker-guided risk stratification, immunophenotyping, pharmacogenomic applications, targeted biologic therapy, and individualized monitoring protocols. Integration of artificial intelligence-assisted diagnostic algorithms, digital dermatology, machine-learning prediction models, and translational immunology may substantially improve diagnostic precision, optimize therapeutic selection, reduce corticosteroid exposure, and enhance maternal–fetal outcomes. Furthermore, multidisciplinary collaboration among dermatologists, obstetricians, maternal–fetal medicine specialists, immunologists, neonatologists, and clinical pharmacists is increasingly recognized as essential for comprehensive patient-centered care. The pemphigoid gestationis remains a rare yet clinically important autoimmune blistering disorder requiring prompt diagnosis, evidence-based pharmacotherapy, individualized therapeutic strategies, and continuous maternal–fetal monitoring. Ongoing advances in immunopathogenesis, molecular diagnostics, targeted immunotherapy, and precision medicine are transforming the clinical management paradigm and hold considerable promise for improving long-term maternal health, neonatal outcomes, and overall quality of life while minimizing disease recurrence and treatment-related complications. Continued translational research, international collaborative studies, and high-quality clinical trials are necessary to establish standardized treatment algorithms and optimize future therapeutic strategies for this uncommon but potentially serious pregnancy-associated autoimmune disease.